glp-1 drugs and gastroparesis New data links agonists for weight loss with higher risk for pancreatitis, GI events Your guide to GLP-1 side

What began as treatments for diabetes and obesity has rapidly expanded into prevention of cardiovascular disease, slowing kidney decline, tackling liver disease, and even tentative explorations into neurodegeneration

Proc Natl Acad Sci US

Keeping a finger on the pulse of this data will help leaders measure the programs ROI while ensuring employees receive the care and support they need. A benefits landscape in flux This is shaping up to be a pivotal year for the GLP-1 drug class, says Campbell, as a number of macro trends will influence the landscape in which HR and benefits leaders are considering plan design and implementation

& Csoka, I

Advancements in drug formulations, synergistic combinations with other antidiabetic medications, and improved safety profiles are poised to drive market expansion during the forecast period